文献速递类风湿关节炎

类风湿关节炎患者使用生物制剂后的淋巴瘤风险:瑞典队列研究

Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该瑞典全国性队列研究纳入16 392例启动bDMARD的RA患者、55 253例未使用bDMARD的RA患者及229 047例匹配的普通人群,评估bDMARD治疗与淋巴瘤及其亚型风险的关系。结果显示bDMARD治疗未进一步增加RA患者的淋巴瘤风险,校正后HR为1.08(95%CI 0.83–1.41),且2006年后启动首个bDMARD者风险可能低于未使用者。

要点

  • bDMARD治疗与未治疗相比,淋巴瘤风险无显著增加(aHR 1.08,95%CI 0.83–1.41)。
  • RA患者总体淋巴瘤风险仍高于普通人群(aHR约1.56–1.65)。
  • 2006年后启动首个bDMARD者风险低于未使用者(aHR 0.69,95%CI 0.47–1.00)。

核心结论

  • bDMARD治疗(包括TNFi和非TNFi)不进一步增加RA患者的淋巴瘤风险,反而可能降低RA中过高的淋巴瘤风险。

研究设计与样本

  • 基于瑞典全国登记数据的队列研究,纳入16 392例启动bDMARD的RA患者、55 253例未使用bDMARD的RA患者和229 047例年龄性别匹配的普通人群对照。

主要发现

  • bDMARD治疗组发生82例淋巴瘤,粗发病率为76/100 000人年;未使用bDMARD组发生310例,粗发病率为90/100 000人年。
  • bDMARD治疗 vs 未治疗的校正HR为1.08(95%CI 0.83–1.41)。
  • bDMARD治疗组和未治疗组 vs 普通人群的校正HR分别为1.65(95%CI 1.31–2.08)和1.56(95%CI 1.37–1.78)。
  • 2006年后启动首个bDMARD vs 未使用bDMARD的校正HR为0.69(95%CI 0.47–1.00);bDMARD治疗 vs 换用另一种csDMARD的校正HR为0.46(95%CI 0.28–0.73)。
  • 未发现特定TNFi药物间风险不同的信号,也未发现bDMARD治疗后淋巴瘤亚型模式不同。

关键数值与推荐

  • bDMARD治疗与未治疗相比,淋巴瘤风险的校正HR为1.08(95%CI 0.83–1.41)。
  • RA患者(bDMARD治疗或未治疗)与普通人群相比,淋巴瘤风险的校正HR分别为1.65(95%CI 1.31–2.08)和1.56(95%CI 1.37–1.78)。
  • 2006年后启动首个bDMARD与未使用bDMARD相比,淋巴瘤风险的校正HR为0.69(95%CI 0.47–1.00)。
  • bDMARD治疗与换用另一种csDMARD相比,淋巴瘤风险的校正HR为0.46(95%CI 0.28–0.73)。

临床怎么用

  • 对于需要bDMARD治疗的RA患者,无需因担忧淋巴瘤风险而避免使用bDMARD。
  • RA患者本身淋巴瘤风险高于普通人群,应关注疾病活动控制,bDMARD治疗可能有助于降低这一超额风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the association between biological DMARDs (bDMARDs; overall and by drug) as used in RA and the risk of malignant lymphomas including subtypes. METHODS: By linking nationwide Swedish registers we identified cohorts of patients with RA initiating treatment with a bDMARD (n = 16 392), bDMARD-naïve (n = 55 253), an age- and sex-matched general population comparator cohort (n = 229 047), and all incident lymphomas 2001-16. We used Cox regression to calculate hazard ratios (HRs) of lymphoma taking calendar period and other factors into account. RESULTS: There were 82 lymphomas among the bDMARD-treated patients with RA, crude incidence rate 76/100 000 person-years, and 310 lymphomas among the bDMARD-naïve patients with RA, crude incidence rate 90/100 000 person-years. This resulted in an adjusted HR (aHR) associated with bDMARD treatment (vs not) of 1.08 (95% CI: 0.83, 1.41). The corresponding aHR for bDMARD-treated and bDMARD-naïve vs the general population was 1.65 (95% CI: 1.31, 2.08) and 1.56 (95% CI: 1.37, 1.78) respectively. Restricting follow-up period to after 2006, the aHR of lymphoma for patients with RA starting a first bDMARD vs bDMARD-naïve was 0.69 (95% CI: 0.47, 1.00), and for bDMARD treated vs patients with RA switching from one conventional synthetic DMARDs to another, aHR was 0.46 (95% CI: 0.28, 0.73). There were no signals of different risks with any particular TNF inhibitor (TNFi) agent. We found no different lymphoma subtype pattern following bDMARD therapy. CONCLUSION: Treatment with bDMARDs, including both TNFi and non-TNFi bDMARDs, does not further increase the lymphoma risk in RA; instead, bDMARD treatment may actually reduce the excess lymphoma risk in RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hellgren K, Di Giuseppe D, Smedby KE, et al. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. Rheumatology (Oxford). 2021. PMID: 32810256. doi:10.1093/rheumatology/keaa330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。